Adial Pharmaceuticals has acquired Azora Therapeutics, a biopharmaceutical company that is developing treatments for serious inflammatory diseases.
With acquisition, Adial gains Azora’s lead asset AT177, which is designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure.
Oppenheimer & Co. is serving as financial advisor to Adial and Blank Rome LLP is serving as legal counsel. Honigman LLP is serving as legal counsel to Azora.